AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers

Molecular Cancer Research

Volumn 15, Issue 1, 2017, Pages 45-58

  Balaji, Kavitha ^a   Vijayaraghavan, Smruthi ^a   Diao, Lixia ^a   Tong, Pan ^a   Fan, Youhong ^a   Carey, Jason P W ^a   Bui, Tuyen N ^a   Warner, Steve ^b   Heymach, John V ^a   Hunt, Kelly K ^a   Wang, Jing ^a   Byers, Lauren Averett ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Tolero Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 7; CHECKPOINT KINASE 2; DOXORUBICIN; FIBRONECTIN; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE AXL; PROTEIN TYROSINE KINASE AXL INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAD51 PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; AXL RECEPTOR TYROSINE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ONCOPROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST EPITHELIUM CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER CELL LINE; MCF CELL LINE; MDA-MB CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85009236699     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0157     Document Type: Article

References (39)

1. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol 2013;5:a009076.
2. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-15.
3. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28:3442-55.
4. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009;8:618-26.
5. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, et al. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology 2015;61:930-41.
6. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. AXL, a transforming gene isolated from primary humanmyeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11: 5016-31.
7. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2014;33: 1316-24.
8. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19:279-90.
9. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.
10. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016;22:609-20.
11. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanismof lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009;69:6871-8.
12. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, et al. Mechanisms of AXL overexpression and function in imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2011;2: 874-85.
13. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, et al. AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:2601-12.
14. Hong J, Peng D, Chen Z, Sehdev V, Belkhiri A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res 2013;73: 331-40.
15. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789-800.
16. Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res 2014;74:5878-90.
17. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, et al. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 2012;132:575-88.
18. Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, et al. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer. Mol Cancer Ther 2016;15:593-607.
19. ZhaoM, SanoD, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17:7248-64.
20. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, et al. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 2012;8:e1002538.
21. Nakanishi K, Cavallo F, Brunet E, Jasin M. Homologous recombination assay for interstrand cross-link repair. Methods Mol Biol 2011;745: 283-91.
22. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, et al. An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors, including DNA repair proteins and Nrf2. Clin Cancer Res 2015;21:3480-91.
23. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
24. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Nonparametric quantification of protein lysate arrays. Bioinformatics 2007; 23:1986-94.
25. Neeley ES, Baggerly KA, Kornblau SM. Surface adjustment of reverse phase protein arrays using positive control spots. Cancer Inform 2012; 11:77-86.
26. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010;28:827-38.
27. Popovici V, Chen W, Gallas BG, Hatzis C, ShiW, Samuelson FW, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010;12:R5.
28. Feneyrolles C, SpenlinhauerA, Guiet L, Fauvel B, Dayde-Cazals B, Warnault P, et al. Axl kinase as a key target for oncology: Focus on small molecule inhibitors. Mol Cancer Ther 2014;13:2141-8.
29. Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol 2014;16:864-75.
30. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A 2009;106:14884-9.
31. Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, et al. Kinomewide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Rep 2015;4:899-913.
32. Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, et al. Tumor cell kill by c-MYC depletion: Role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 2010;70: 8748-59.
33. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011;10:1192-9.
34. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.
35. Kurokawa M, Ise N, Omi K, Goishi K, Higashiyama S. Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelialmesenchymal transition-like changes. Cancer Sci 2013;104:904-11.
36. Scaltriti M, Elkabets M, Baselga J. Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy. Clin Cancer Res 2016; 22:1313-7.
37. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 2014;124:2696-708.
38. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Disease 2013; 4:e875.
39. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Devel 2002;16:245-56.